Lead Product(s) : Certolizumab Pegol
Therapeutic Area : Rheumatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
March 16, 2010
Lead Product(s) : Certolizumab Pegol
Therapeutic Area : Rheumatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable